Applied DNA Sciences Future Growth

Future criteria checks 2/6

Applied DNA Sciences's earnings are forecast to decline at 7.1% per annum while its annual revenue is expected to grow at 21.9% per year. EPS is expected to grow by 64.8% per annum.

Key information

-7.1%

Earnings growth rate

64.8%

EPS growth rate

Life Sciences earnings growth	16.9%
Revenue growth rate	21.9%
Future return on equity	n/a
Analyst coverage	Low
Last updated	13 May 2024

Recent future growth updates

Recent updates

The Market Doesn't Like What It Sees From Applied DNA Sciences, Inc.'s (NASDAQ:APDN) Revenues Yet As Shares Tumble 26%

Dec 20

Upgrade: Analysts Just Made A Notable Increase To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts

Aug 17

Applied DNA Sciences gains as it secures ~$3.6M proceeds from warrant exercise

Aug 09

Applied DNA stock soars 73% on starting validation of PCR-based monkeypox test

Aug 02

Applied DNA announces positive data from veterinary vaccine trial to treat COVID-19

Jul 25

News Flash: Analysts Just Made A Notable Upgrade To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts

May 18

Is Applied DNA Sciences (NASDAQ:APDN) In A Good Position To Deliver On Growth Plans?

Sep 17

Earnings and Revenue Growth Forecasts

NasdaqCM:APDN - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2025	7	-14	N/A	N/A	2
9/30/2024	5	-12	N/A	N/A	1
3/31/2024	6	-13	-12	-11	N/A
12/31/2023	9	-7	-9	-8	N/A
9/30/2023	13	-10	-7	-6	N/A
6/30/2023	16	-7	-7	-7	N/A
3/31/2023	18	-5	-8	-7	N/A
12/31/2022	19	-7	-8	-8	N/A
9/30/2022	18	-8	-9	-9	N/A
6/30/2022	18	-12	-12	-10	N/A
3/31/2022	15	-15	-12	-10	N/A
12/31/2021	12	-14	-15	-13	N/A
9/30/2021	9	-14	-16	-13	N/A
6/30/2021	6	-14	-14	-12	N/A
3/31/2021	5	-14	-16	-13	N/A
12/31/2020	3	-15	-14	-13	N/A
9/30/2020	2	-13	-12	-11	N/A
6/30/2020	3	-10	-10	-10	N/A
3/31/2020	5	-9	-8	-8	N/A
12/31/2019	5	-8	-8	-8	N/A
9/30/2019	5	-9	-7	-7	N/A
6/30/2019	5	-11	-8	-8	N/A
3/31/2019	4	-12	-8	-7	N/A
12/31/2018	4	-12	-6	-6	N/A
9/30/2018	4	-12	-7	-7	N/A
6/30/2018	4	-11	-6	-5	N/A
3/31/2018	5	-11	-6	-6	N/A
12/31/2017	4	-12	N/A	-8	N/A
9/30/2017	5	-13	N/A	-7	N/A
6/30/2017	5	-12	N/A	-9	N/A
3/31/2017	4	-13	N/A	-9	N/A
12/31/2016	4	-13	N/A	-9	N/A
9/30/2016	4	-12	N/A	-10	N/A
6/30/2016	7	-10	N/A	-9	N/A
3/31/2016	8	-9	N/A	-8	N/A
12/31/2015	9	-7	N/A	-7	N/A
9/30/2015	9	-12	N/A	-7	N/A
6/30/2015	6	-13	N/A	-7	N/A
3/31/2015	4	-14	N/A	-8	N/A
12/31/2014	3	-15	N/A	-9	N/A
9/30/2014	3	-13	N/A	-9	N/A
6/30/2014	3	-15	N/A	-8	N/A
3/31/2014	3	-15	N/A	-8	N/A
12/31/2013	2	-15	N/A	-8	N/A
9/30/2013	2	-18	N/A	-8	N/A
6/30/2013	2	-16	N/A	-7	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: APDN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: APDN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: APDN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: APDN's revenue (21.9% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: APDN's revenue (21.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if APDN's Return on Equity is forecast to be high in 3 years time

Applied DNA Sciences Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus estimates of losses per share improve by 24%

Consensus EPS estimates upgraded to US$0.65 loss, revenue downgraded

Consensus revenue estimates fall by 49%

Consensus revenue estimates decrease by 13%, EPS upgraded

Consensus revenue estimates increase by 12%

Consensus revenue estimates fall by 20%

Recent updates

Consensus estimates of losses per share improve by 24%

Applied DNA Sciences, Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering.

Applied DNA Sciences, Inc. to Showcase Linea DNA and Linea IVT Platforms At 24Th Annual World Vaccine Congress

Consensus EPS estimates upgraded to US$0.65 loss, revenue downgraded

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Shareholder dilution

Applied DNA Sciences, Inc. to Report Q1, 2024 Results on Feb 08, 2024

Applied DNA Sciences, Inc., Annual General Meeting, Apr 15, 2024

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $3.436992 million.

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $3.437233 million.

The Market Doesn't Like What It Sees From Applied DNA Sciences, Inc.'s (NASDAQ:APDN) Revenues Yet As Shares Tumble 26%

Consensus revenue estimates fall by 49%

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Applied DNA Sciences Receives Non-Compliance Notice From Nasdaq

Applied DNA Sciences, Inc. to Report Q4, 2023 Results on Dec 07, 2023

Applied DNA Sciences, Inc. Extends Application of Linea(Tm) Ivt Platform to Sna (Self-Amplifying Mrna)

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.397939 million.

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.397939 million.

Applied DNA Sciences, Inc. Announces Appointment of Beverly Wolgast as Executive Director of Quality and cGMP Programs

Applied DNA Sciences, Inc. Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit

Applied DNA Sciences, Inc. Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Applied DNA Sciences, Inc. to Report Q3, 2023 Results on Aug 10, 2023

Applied DNA Sciences, Inc., Annual General Meeting, Sep 19, 2023

New minor risk - Share price stability

Applied DNA Sciences, Inc. (NasdaqCM:APDN) acquired Spindle Biotech Inc. for $2.8 million.

Consensus revenue estimates decrease by 13%, EPS upgraded

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Applied DNA Sciences, Inc. to Report Q2, 2023 Results on May 11, 2023

Consensus revenue estimates increase by 12%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Applied DNA Sciences, Inc. to Report Q1, 2023 Results on Feb 09, 2023

Applied DNA Sciences, Inc. Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA as New Class of DNA-Based Vaccines

Is Applied DNA Sciences (NASDAQ:APDN) In A Good Position To Invest In Growth?

Consensus revenue estimates fall by 20%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Price target decreased to US$7.00

Applied DNA Sciences, Inc. to Report Q4, 2022 Results on Dec 05, 2022

Applied DNA climbs 51% after winning large purchase order

Applied DNA Sciences, Inc.'s Subsidiary, Applied DNA Clinical Labs, LLC, Launches Monkeypox Testing Service

Applied DNA stock rises 12% on launching monkeypox testing service in New York

Applied DNA Submits PCR-Based Monkeypox Virus Diagnostic Test for Approval to New York State Department of Health

Applied DNA adds 17% as company seeks approval for monkeypox test in New York

Consensus estimates of losses per share improve by 19%

Upgrade: Analysts Just Made A Notable Increase To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Applied DNA Sciences gains as it secures ~$3.6M proceeds from warrant exercise

Price target decreased to US$5.00

Applied DNA stock soars 73% on starting validation of PCR-based monkeypox test

Applied DNA Sciences, Inc. Announces Retirement of John Bitzer from Board of Directors

Applied DNA announces positive data from veterinary vaccine trial to treat COVID-19

Applied DNA Sciences, Inc. Launches Initiatives to Expand Awareness of LinearDNA Platform as Alternative to Plasmid DNA for Therapeutic Applications, Revamps LineaRx Website

Applied DNA and Evvivax Announce Peer-Reviewed Publication of Positive Preclinical Data for LinearDNA Platform

Consensus revenue estimates increase by 20%

News Flash: Analysts Just Made A Notable Upgrade To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Applied DNA Sciences, Inc. to Report Q2, 2022 Results on May 12, 2022

Price target decreased to US$12.00

Applied DNA Sciences, Inc. and EvviVax, S.R.L. Announce Publication of Positive Preclinical Data for LinearDNA™ Platform Approach to Cancer Immunotherapy

Consensus forecasts updated

Price target decreased to US$16.00

Applied DNA Sciences, Inc. to Report Q1, 2022 Results on Feb 10, 2022

Applied DNA Sciences, Inc. to Deploy Linea™ 1.0 COVID-19 Assay for Rapid Detection of New Omicron Subvariant BA.2

Consensus forecasts updated